January 28, 2020 Acceleron’s post-Reblozyl plan comes together Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.
November 29, 2018 FDA decision time looms for Gelesis Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
